Targeted sustained delivery of antineoplastic agent with multicomponent polylactide stereocomplex micelle

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapy

Background:

• Targeted drug delivery systems are crucial for improving cancer treatment efficacy and minimizing side effects.
• Polylactide stereocomplex micelles offer a versatile platform for drug encapsulation and controlled release.
• The αvβ3 integrin is overexpressed in various cancers, making it a potential target for cancer therapy.

Purpose of the Study:

• To develop and evaluate a c(RGDfC)-decorated polylactide stereocomplex micelle (cRGD-SCM) for targeted delivery of doxorubicin (DOX) to αvβ3 integrin-positive C26 colon cancer.
• To investigate the in vivo performance of cRGD-SCM/DOX, including its circulation time, tumor accumulation, therapeutic efficacy, and safety profile.
• To demonstrate the potential of this platform for personalized chemotherapy by highlighting the replaceability of the targeting ligand.

Main Methods:

• Preparation of cRGD-SCM using 4-arm poly(ethylene glycol)-block-poly(D-lactide) (4-arm PEG-b-PDLA), methoxy poly(ethylene glycol)-block-poly(L-lactide) (mPEG-b-PLLA), and cRGD-PEG-b-PLLA.
• Loading of doxorubicin (DOX) into cRGD-SCM, achieving a drug loading efficiency of 45.9wt.% and a particle size of approximately 100nm.
• In vivo evaluation of cRGD-SCM/DOX in C26 colon cancer models, comparing its performance against free DOX and non-targeting SCM/DOX.

Main Results:

• cRGD-SCM/DOX exhibited a sustained drug release pattern.
• The targeted micelles demonstrated prolonged circulation time and enhanced accumulation in tumors compared to controls.
• Significant tumor inhibition and reduced side effects were observed with cRGD-SCM/DOX in vivo.

Conclusions:

• c(RGDfC)-decorated polylactide stereocomplex micelles serve as an effective targeted drug delivery system for αvβ3 integrin-positive colon cancer.
• The developed platform shows potential for enhanced chemotherapy efficacy and improved safety profiles.
• The modular nature of the targeting ligand allows for adaptation to various cancer types, paving the way for personalized medicine.